Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Q BioMed Enters $7.8M Financial Restructuring | Contract Pharma

What are you searching for?

Sign in
Breaking News

Q BioMed Enters $7.8M Financial Restructuring

Provides capital to bring FDA approved non-opioid, Strontium89 Chloride USP Injection drug to market.

By: Contract Pharma

Contract Pharma Staff

Q BioMed Inc., a commercial stage biotech company, has completed a financial restructuring of approximately $7.8 million with its lead investor, Yorkville Advisors Global (YA).

This restructuring of debt and new capital will provide for the company to implement its full commercial plan as it brings its FDA approved non-opioid, Strontium89 Chloride USP Injection drug to market. 

Denis Corin, QBioMed CEO said, “In addition to the rollout of our Strontium89 drug, this funding allows us to advance other key pipeline assets such as our infectious disease platform including a potential treatment for COVID-19, influenza and others, liver cancer therapy Uttroside B and our rare disease drug development in non-verbal autism spectrum disorders.”

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters